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Abstract. Biomarkers are indicators of biological processes and hold promise for the diagnosis and treatment of
disease. Gliomas represent a heterogeneous group of brain tumors with marked intra- and inter-tumor variability.
The extent of surgical resection is a significant factor influencing post-surgical recurrence and prognosis. Here,
we used fluorescence and reflectance spectral signatures for in vivo quantification of multiple biomarkers during
glioma surgery, with fluorescence contrast provided by exogenously-induced protoporphyrin IX (PpIX) following
administration of 5-aminolevulinic acid. We performed light-transport modeling to quantify multiple biomarkers
indicative of tumor biological processes, including the local concentration of PpIX and associated photoproducts,
total hemoglobin concentration, oxygen saturation, and optical scattering parameters. We developed a diagnostic
algorithm for intra-operative tissue delineation that accounts for the combined tumor-specific predictive capa-
bilities of these quantitative biomarkers. Tumor tissue delineation achieved accuracies of up to 94% (specificity
= 94%, sensitivity = 94%) across a range of glioma histologies beyond current state-of-the-art optical approaches,
including state-of-the-art fluorescence image guidance. This multiple biomarker strategy opens the door to opti-
cal methods for surgical guidance that use quantification of well-established neoplastic processes. Future work
would seek to validate the predictive power of this proof-of-concept study in a separate larger cohort of patients.
C©2011 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.3646916]
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1 Introduction
Gliomas are the most common of primary brain tumors, ac-
counting for over 60% of all cases. More efficient and accurate
tumor detection can improve diagnosis and lead to advances in
the treatment and management of disease.1–5 Biomarkers hold
therapeutic and diagnostic promise, in particular, those for in-
traoperative tumor detection4–7 during surgeries in which the
extent of resection is a significant factor influencing prognosis
and local recurrence of disease.3, 8–10
Optical methods offer a wide range of detection technolo-
gies and strategies that exploit tumor-specific optical biomark-
ers that have the potential to improve intra-operative tumor
identification for guiding surgical intervention. For example,
high-grade gliomas accumulate the endogenous biomarker pro-
toporphyrin IX (PpIX) following exogenous administration of
5-aminolevulinic acid (ALA), resulting in increased tumor tis-
sue fluorescence. Despite considerable success with PpIX in
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Thayer School of Engineering, 8000 Cummings Hall, Hanover, New
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guiding the resection of these tumors, current fluorescence de-
tection has suffered from low sensitivity, likely due to the rel-
atively low intensity of fluorescence signals and the subjective
assessment relative to a complex tissue background. Sensitivity
limitations lead to incomplete tumor detection, i.e., resectable
tumor tissue is left undetected, which may be the main rea-
son that resulting ALA-induced PpIX fluorescence imaging has
only been useful for tumor subtypes that accumulate relatively
high PpIX concentrations (i.e., high grade gliomas).4, 7, 10–14 We
recently reported quantitative measurements of in vivo PpIX
concentrations in human brain tumors that showed that diag-
nostically significant levels do occur across a range of intracra-
nial tumor histologies (including low- and high-grade gliomas,
meningiomas, and metastases) even when not visibly evident to
the surgeon. Despite the improvement in diagnostic accuracy to a
degree comparable to that of visible fluorescence for high grade
disease, the performance in lower grade gliomas needs further
improvement.7 Nonetheless, these data demonstrated for the first
time that ALA-induced PpIX fluorescence has the potential to
improve surgery even for low-grade gliomas.
1083-3668/2011/16(11)/116007/14/$25.00 C© 2011 SPIE
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Neoplastic processes, e.g., metabolic-profile changes, abnor-
mal vasculature formation, tissue hypoxia, increased cellular
proliferation, and differential gene expression profiles, provide a
variety of potential biomarker targets.2, 4, 5, 15–17 However, inter-
and intra-tumor differences coupled to current technological
limitations, have diluted the potential of these biomarkers for
in vivo tumor detection. Furthermore, the multifaceted character-
istics of tumor biology and glioma pathophysiology suggest that
any single biomarker is unlikely to provide the required speci-
ficity and sensitivity for universal tumor tissue identification.
Here, we measured multiple optical chromophores/fluorophores
and scattering parameters in vivo that are potentially predictive
of neoplastic processes and combined them in an algorithm
for tumor identification during glioma resection surgery with a
diagnostic performance that is superior to intraoperative fluores-
cence state-of-the-art imaging. The measured quantities com-
prised total hemoglobin, oxygen saturation, and optical scatter-
ing (related to tissue microstructure) derived from the optical
reflectance spectra, and concentration of PpIX and associated
photoproducts (related to cell metabolism) determined from the
quantitative fluorescence spectra. We believe that combining this
information into a single diagnostic indicator provides a more
comprehensive biologically relevant approach to intraoperative
optical tumor tissue detection. Although the data reported here is
promising, future studies are required to validate the predictive
power of the algorithm on a much larger cohort of patients.
2 Materials and Methods
2.1 Patient Selection
The Dartmouth-Hitchcock Medical Center Committee for the
Protection of Human Subjects approved this study under a
fluorescence-guided brain tumor resection protocol.7, 12, 18 All
patients participated under informed consent. Patients with a di-
agnosis of low-grade glioma (LGG), high-grade glioma (HGG),
or recurrent glioma (RCG) were administered an oral dose
(20 mg/kg body weight) of ALA (DUSA Pharmaceuticals,
Tarrytown, New York) dissolved in 100 ml of water approxi-
mately three hours prior to the induction of anesthesia. High-
resolution post-gadolinium injection pre-operative T1- or T2-
weighted magnetic resonance images were acquired and used
for standard neuronavigation.
2.2 Surgical Procedure
The patient was prepared for intracranial tumor resection follow-
ing standard practice.12 The head was spatially registered with
the pre-operative magnetic resonance images using a StealthSta-
tion Treon (Medtronic, Louisville, Colorado) for image-guided
neuronavigation, which relates the position of the focal point of
the surgical microscope to the surgical field and image-space co-
ordinates. A Zeiss OPMI Pentero (Carl Zeiss Surgical, GmbH,
Oberkochen, Germany) microscope, modified for blue light (flu-
orescence) imaging, allowed the surgeon to rapidly switch be-
tween white-light and fluorescence modes during the procedure.
The microscope is equipped with a 400-nm blue light source
for PpIX fluorescence excitation; detection is achieved using a
three-chip CCD camera, in front of which optical interference
filters are placed. PpIX has a fairly broad fluorescence emission
in the red region of the spectrum and a relatively low quantum
efficiency (<0.01), and this instrumentation allows real-time flu-
orescence images to be acquired within the spectral range from
620 to 710 nm.
At various times during resection, the surgeon switched from
white light to blue light to visualize fluorescence.7, 12, 18 The
coregistered operating microscope was then focused on a point
of interest for optical and tissue sampling. Digital images were
recorded in both white- and blue-light modes and a biopsy spec-
imen was acquired at the same location (i.e., focal point of the
coregistered operating microscope). Immediately prior to digital
image and biopsy acquisition, the surgeon irrigated the location
of the intended specimen to ensure clearing of blood and de-
bris, placed the intraoperative fluorescence/reflectance probe at
the focal point of the operating microscope (see Sec. 2.3), and
performed readings (<0.5 s per acquisition) of the fluorescence
and diffuse reflectance spectra in triplicate.7 Each biopsy site
was assigned a qualitative visible fluorescence score from 0 to
4 (0 = no visible fluorescence, 1 = minimal fluorescence, 2
= moderate fluorescence, 3 = high fluorescence, 4 = very high
fluorescence) based on the subjective impression of the surgeon
of the visible fluorescence before tissue removal. The surgeon
(D. W. Roberts) had experience in using this fluorescence imag-
ing system on over 70 patients. Biopsy samples were collected
at the beginning, middle, and end of resection from areas that
displayed both visible (red) fluorescence contrast (if present),
as well as nonvisible fluorescent regions that were part of the
planned resection volume. Control data were also acquired in
each case consisting of spectroscopic measurements in normal
brain without a corresponding biopsy.
The biopsy specimens were separated into three equal parts
for further processing: one part was placed in formalin, one
in optimal cutting temperature compound and frozen in liquid
nitrogen, and the final part was placed in a cryogenic vial and
frozen in liquid nitrogen. Methodological details can be found
in Valdes et al.7
2.3 In Vivo Optical Probe Measurements
and Quantification
An intra-operative hand-held optical probe was used to provide
the surgeon with quantitative in vivo and in situ pathophysiolog-
ical data that is complementary to the qualitative fluorescence
information derived from the state-of-the-art neurosurgical mi-
croscope described in Sec. 2.2.
2.3.1 Instrumentation
The spectroscopic probe developed for intraoperative fluores-
cence and diffuse reflectance measurements7, 19, 20 (A. Kim and
B. C. Wilson) is illustrated in Fig. 1. It is comprised of four opti-
cal fibers linearly arranged at the tip and 260 μm apart (center-to-
center). Two fibers act as white light sources located d = 260 and
520 μm apart from a third detection fiber. The latter is con-
nected to a spectrometer (USB2000 + : OceanOptics, Dunedin,
Florida) with 0.35 nm spectral resolution. The fourth fiber serves
as a blue light source located at d = 260 μm from the detector
fiber. Each fiber consists of a 200-μm diameter silica core with
a numerical aperture of 0.22. The fibers were bundled into an
18-gauge stainless steel shaft forming the tissue-contact end of
the probe and connected to a software-controlled data acquisi-
tion system through a 3-m long cable. White-light reflectance
spectra (450 to 720 nm) and fluorescence emissions (600 to
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Fig. 1 Conceptual diagram of the probe measurements and data analysis. Data Acquisition (left): The intraoperative fiber optic probe with a
tip diameter of ∼1.1 mm is gently placed on the clean tissue surface. Sequential interrogation with white and blue light allows collection of
diffuse reflectance and fluorescence spectra using a spectrometer (<0.5 s). Data Analysis: White-light reflectance data are input to a spectrally-
constrained optical model to calculate the tissue optical absorption and scattering at each wavelength. These are used to correct the measured
fluorescence spectrum for variations in tissue optical properties and to generate the quantitative fluorescence spectrum from which the fluorophore
concentrations can be calculated (∼1 s). The calculated biomarker values (e.g., cPpIX, cPps, and cHb) are used in a SVM-based diagnostic algorithm
to classify interrogated regions as normal tissue or tumor.
720 nm) following 405 nm excitation light were sequentially
collected during each measurement. As described in detail in
Kim et al.,19, 20 two white-light spectra, corresponding to differ-
ent source-detector separations, are used to improve the accuracy
of the tissue absorption and scattering spectra obtained from a
light-transport model19, 20 (Fig. 1).
2.3.2 Light-transport modeling
Light-transport modeling was used to estimate the tissue optical
absorption and elastic scattering properties from the white-light
diffuse reflectance spectra. Optical characterization is achieved
assuming that light propagation in tissue is described by the dif-
fusion equation for boundary conditions consistent with a semi-
infinite, homogeneous, optically-turbid medium.19 Tissue can
then be characterized by the optical properties of the absorption
coefficient, μa(λ), and the reduced scattering coefficient, μs′(λ).
These properties can be estimated at each wavelength from the
white-light reflectance and then applied to the measured fluores-
cence spectra to correct for their distorting effects.21–23 The es-
timation is achieved by minimizing the error between the probe
measurements and a spectrally-constrained model of the diffuse
reflectance with a Levenberg-Marquardt nonlinear curve fitting
algorithm. The resulting quantitative (corrected) fluorescence
spectrum was obtained from the model.
This corrected and quantitative fluorescence spectrum was
then decomposed into 1. PpIX, 2. photoproducts that are
generated during intraoperative exposure of PpIX to the
operating lights,24 and 3. the tissue autofluorescence due to
endogenous molecules. The PpIX concentration at the tissue
measurement point was calculated from the “corrected” PpIX
spectrum using the known fluorescence spectrum of PpIX at unit
concentration.19
The derived absorption and scattering spectra were analyzed
to extract the intrinsic optical biomarker values. The absorption
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spectra can be represented by
μa(λ) = cHb[St O2μa(λ)oxy Hb + (1 − St O2)μa(λ)deoxy Hb],
(1)
where μa(λ)oxyHb and μa(λ)deoxyHb are the wavelength-dependent
absorption (extinction) coefficients of oxy- and deoxy-
hemoglobin at concentrations of 1 g/mL, cHb represents the
total hemoglobin concentration, and StO2 is the oxygen satura-
tion fraction (the ratio of oxyhemoglobin to total hemoglobin
concentration).
The reduced scattering coefficient of tissue is represented by
a wavelength-dependent power law,
μ′s(λ) = SAλ−Sp , (2)
where SA is the scattering amplitude and SP is the scatter-
ing power. A forward model of diffuse reflectance and the
a priori absorption and scattering spectra are combined, and a
Levenberg-Marquardt nonlinear curve fitting algorithm is used
to extract the free parameters: total hemoglobin concentration,
oxygen saturation, scattering amplitude, and scattering power
(Fig. 1). Further details on the algorithm can be found in
Kim et al.19
2.4 Neuropathological Assessment
Histopathological analysis was performed by an experienced
neuropathologist (B. T. Harris) on each biopsy specimen.
Formalin-fixed, paraffin-embedded tissues were processed for
hematoxylin and eosin (H&E) staining. Each H&E section was
assessed for the presence of tumor cells, necrosis, and reactive
astrocytosis. Tissue samples were classified as normal or ab-
normal (tumor) based on World Health Organization (WHO)
histopathological criteria.25 Biopsy specimens were categorized
as either normal tissue, low-grade glioma (WHO grade I or II),
high-grade glioma (WHO grade III or IV), or RCG. The recur-
rent glioma category consisted of patients who had previously
undergone treatment (e.g., surgery, chemotherapy, and/or radia-
tion) and presented tumor recurrence at the time of their second
surgery. A fifth diagnostic category, labeled all gliomas (AG),
was introduced to group all abnormal biopsy specimens together
for comparison with normal control measurements.
2.5 In Vivo Optical Data Analysis
Prior to biopsy acquisition, in vivo optical measurements were
acquired at multiple locations in the surgical cavity. The in situ
intraoperative probe data associated with each biopsy acquisi-
tion were grouped based on the neuropathological assessment
(e.g., tumor or normal) of their corresponding specimens.
The raw optical data acquired with the probe consisted of two
reflectance spectra and one fluorescence spectrum. Analyses us-
ing the methods described in Sec. 2.3.2 (a combination of light
transport modeling and curve fitting algorithms) allowed quanti-
tative information to be derived from these raw spectra. Specifi-
cally, concentrations of oxygenated hemoglobin, de-oxygenated
hemoglobin, and PpIX and associated decay photoproducts re-
sulting from the interaction of the excitation light with the tissue
were calculated. This molecular information was complemented
with measures of the tissue autofluorescence and effective scat-
tering properties.
For each probe measurement, the white-light reflectance
spectrum for which the source-detector distance was
d = 260 μm is labeled R1(λ) and for which d = 520 μm is
labeled R2(λ). For each probe acquisition, a background mea-
surement of the ambient light was acquired and systematically
subtracted from the reflectance spectra as well as the raw fluores-
cence spectrum, Fu(λ), in the range 450 to 720 nm. Instrument
and data calibration were performed as described in detail in
Kim et al.19, 20
The model-derived optical spectra consisted of the absorp-
tion spectra, μa(λ), and reduced scattering spectra, μs′(λ), in the
range 450 to 720 nm and diffuse reflectance spectra, Rt,x(λ), in
the range 450 to 720 nm for each interrogated site. The model-
derived quantities that were analyzed included the PpIX con-
centration (cPpIX), PpIX photoproduct concentration (cPps), to-
tal hemoglobin concentration (cHb), oxygen saturation fraction
(StO2), scattering amplitude (SA), and scattering power (SP).
2.6 Data and Statistical Analyses
Kolmogorov-Smirnov tests were used to ascertain normality
of distributions. Wilcoxon-rank sum (Mann-Whitney) analyses
were used to compare differences between spectral peaks and
the derived biomarkers. Receiver operating characteristic (ROC)
analysis was used to determine the area under the curve (AUC).
This metric serves to quantify and summarize the diagnostic
performance with AUC = 1.00 corresponding to perfect classi-
fication and AUC = 0.50 representing classification not signif-
icantly different from chance. The specificity, sensitivity, nega-
tive predictive value, and positive predictive value for qualitative
visual fluorescence and cPpIX are dependent on the chosen cut-off
value and we used a standard methodology for determining the
cut-off associated with optimal classification efficiency.26 Data
were processed and analyzed with MATLAB R© software and its
Bioinformatics Toolbox (Version 2010a, The Mathworks Inc.,
Natick, Massachusetts). Two-sided P-values <0.05 are consid-
ered statistically significant.
2.7 Diagnostic Algorithm
We developed a physiologically-relevant diagnostic algorithm
composed of the five model-derived biomarkers. Previous stud-
ies of the brain have used various combinations of raw optical
spectral peaks and peak ratios, wavelength-dependent average
fluorescence lifetimes, and model-derived diffuse reflectance
peaks as predictor variables in multivariate classification algo-
rithms (e.g., linear discriminant analysis).15, 27–41 In this study,
we chose quantitative biomarkers associated with neoplastic
changes as variables and hypothesized that inclusion of multiple
biomarkers, which individually show significant, albeit limited,
classification potential, provides optimal detection accuracy.
To this end, a diagnostic algorithm for tissue classification
was developed using support vector machines (SVM).42–45 SVM
algorithms are commonly used in general nonlinear classifica-
tion problems in which predictor variables capture important
characteristics of an individual data point. As summarized in
Appendix A, SVM is a mathematical framework for generat-
ing relationships between data characteristics and a property of
interest not previously known based on rules for classification
derived from a training set of data points where the optimal
parameters are determined by cross-validation (e.g., leave-one-
out). The algorithm then applies the derived classification rules
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to new data points of unknown class and assigns class member-
ship.
2.7.1 Dataset training and testing
The dataset (n = 264 data points) was organized into two cat-
egories: normal (i.e., control normal brain) and abnormal (i.e.,
LGG, HGG, RCG) tissue. We used an SVM algorithm in a
leave-one-out, cross-validation approach to classify tissue in
which intraoperative probe data for one interrogated site was
left out of the dataset. The algorithm derived from this training
phase was subsequently applied to the data point left out (test-
ing phase), a cut-off value was calculated, and the tissue was
classified. This process was repeated with each individual inter-
rogated site being left-out to build a 2-by-2 table from which the
overall classification efficiency of the multiple biomarker-based
diagnostic algorithm was determined and the accuracy, speci-
ficity, sensitivity, and positive and negative predictive values
were calculated.
3 Results
3.1 Neuropathology
Intraoperative probe data were collected on 10 patients un-
dergoing fluorescence-guided resection: five with high-grade
gliomas (HGG-glioblastoma multiforme), two with low-grade
glioma (LGG-mixed oligoastrocytomas) and three with RCGs.
Tissue specimens from all recurrent glioma patients displayed
histopathological characteristics meeting high-grade WHO cri-
teria. A total of 88 sites were interrogated with the probe (each
in triplicate) resulting in 264 spectra acquired from 26 control
and 62 tumor locations.
3.2 In Vivo Optical Data
3.2.1 Raw optical data
The median spectra and interquartile range for R1(λ), R2(λ),
and Fu(λ) was calculated for normal (i.e., controls) and tu-
mor (i.e., LGG, HGG, RCG) tissue. Wilcoxon rank-sum anal-
ysis was used to assess differences in spectral regions for
R1(λ), R2(λ), and Fu(λ) in the range λ = 450 to 720 nm. For
R1(λ) and R2(λ), the whole spectrum in the range λ = 450 to
720 nm showed statistically significant differences between nor-
mal and tumor data with the most pronounced differences ob-
served in the region corresponding to the two major absorption
peaks for hemoglobin (range λ = 450 to 580 nm) (P < 0.00001).
For Fu(λ), statistically significant differences occurred when λ
< 610 nm and λ = 650 to 680 nm. We also performed an ROC
analysis and found regions for R1(λ) and R2(λ) with the highest
classification efficiency for differentiating normal tissue from
tumor (AUC values were 0.70 and 0.75, respectively) resulted
when λ = 450 to 580 nm. For Fu(λ), regions with the highest
classification efficiency had λ < 610 nm and λ = 650 to 680 nm
(AUC values were 0.75 and 0.65, respectively) (Fig. 2).
3.2.2 Model-derived optical spectra
The median spectra and interquartile range for μs′(λ), μa(λ),
and Rt,x(λ) were calculated from normal and tumor measure-
ments. Wilcoxon-rank sum analysis was performed to assess
differences in the spectral range λ = 450 to 720 nm for μa(λ),
μs
′(λ), and Rt ,x(λ). For μa(λ), a highly statistically significant
difference (P < 0.00001) occurred in the range λ = 450 to
720 nm, whereas μs′(λ) showed a less pronounced but still statis-
tically significant difference (P < 0.05). For Rt ,x(λ), statistically
significant differences between normal tissue and tumor resulted
over the range λ = 450 to 720 nm with the most pronounced
differences occurring when λ = 450 to 580 nm (P < 0.00001).
We also performed ROC analysis and found differences in
Rt ,x(λ) with the highest classification efficiency occurring when
λ = 450 to 580 nm (AUC values of approximately 0.65). The
AUC values for differences in μa(λ) were approximately 0.65
in the range λ = 450 to 580 nm with a maximum of approxi-
mately 0.75 for λ = 600 to 720 nm (Fig. 3). The AUC values for
the differences in μs′(λ) were approximately 0.60 over the full
spectrum.
3.2.3 Model-derived optical biomarkers
The median value and interquartile range for cPpIX, cPps, cHb,
StO2, SA, and SP were calculated for normal tissue and tu-
mor and Wilcoxon-rank sum analysis was performed to assess
their differences. Statistically significant increases occurred in
cPpIX, (P < 0.0001), cPps (P < 0.0001), cHb (P < 0.01), and
SP (P < 0.0001) in tumor compared to normal tissues, and a
statistically significant decrease (P < 0.0001) resulted in StO2.
No significant difference was observed in SA (P = 0.2049)
(Fig. 4). Hence, we chose to include cPpIX, cPps, cHb, StO2, and
SP as predictor variables in the diagnostic algorithm.
3.3 Diagnostic Algorithm Classification
We developed an SVM diagnostic algorithm based on multiple
biomarkers, which was trained and tested on n = 264 data points
(i.e., three spectra for each interrogated site) using leave-one-
out cross-validation; these results included 78 control and 186
glioma recordings (Fig. 4). We compared the diagnostic per-
formance of this multiple biomarker algorithm to the qualita-
tive visual assessment of fluorescence intraoperatively obtained
and the quantitative measurement of PpIX concentration alone.
Table 1 contains a summary of the AUCs for all gliomas as
well as the low-grade, high-grade, and recurrent glioma cate-
gories for the three approaches. The optimal classification effi-
ciency for qualitative visual fluorescence was 64% (specificity
= 96%, sensitivity = 50%, positive predictive value = 97%,
and negative predictive value = 45%) and for the quantitative
cPpIX data was 83% (specificity = 78%, sensitivity = 84%,
positive predictive value = 90%, and negative predictive value
= 68%) compared to 94% for the multiple biomarker algorithm
(specificity = 94%, sensitivity = 94%, positive predictive value
= 97%, and negative predictive value = 87%) (Table 2).
Further, we performed ROC analysis to compare the diag-
nostic performance of qualitative visual imaging, cPpIX, and our
multiple biomarker strategy. The classification algorithm was
significantly more accurate with AUC = 0.94 (0.02) than qualita-
tive visual assessment of fluorescence with AUC = 0.72(0.03) (P
< 0.00001), and than our previously reported cPpIX biomarker-
only approach with AUC = 0.87(0.03) (P = 0.0055). In this
study, the cut-off value with the best discrimination for cPpIX
was chosen as the point on the curve closest to the upper left
corner of the ROC graph following standard practice and as pre-
viously reported in Valdes et al.7 A different cut-off value (e.g.,
higher cPpIX) could be chosen with concomitant changes in (e.g.,
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(a) (b)
(c) (d)
(e) (f)
Fig. 2 Raw fluorescence and reflectance spectra. The median spectra for each of Fu(λ) (A,B), R1(λ) (C,D), and R2(λ) (E,F) were calculated for normal
(blue line) and tumor (red line) tissue. Error bars represent the interquartile range. P-values from the Wilcoxon-rank sum analysis are indicated by
the black line, left column, with the green horizontal line crossing at P = 0.05. Associated AUC values are shown as the black line, right column.
(Color online only.)
decreasing) sensitivity and (e.g., increasing) specificity. Table 2
summarizes the diagnostic performance of the three approaches
in terms of these quantities.
4 Discussion
4.1 Optical Strategies for Brain Tumor Surgery
Wide-field qualitative visual fluorescence,4, 10, 12, 13, 46–52
semi-quantitative fluorescence and/or white-light spec-
tral characteristics,15, 27–41 and quantitative chromophore/
fluorophore concentrations and/or tissue optical properties are
under investigation as tools and/or data for providing intraop-
erative guidance during brian tumor resection procedures.7, 53
The most common and well-developed approach incorporates
wide-field imaging to visualize PpIX fluorescence during the
resection of high-grade gliomas. Exogenous administration
of ALA leads to selective accumulation of PpIX. Blue-light
excitation followed by collection of the red fluorescence
emissions visible to the surgeon is used to guide resection
decisions.10, 12, 13, 53
Most studies of tissue discrimination through spectral
characteristics have used “raw” fluorescence (endogenous or
exogenously-induced) and/or white-light reflectance spectra
corrected for instrument response. Various research groups have
Journal of Biomedical Optics November 2011  Vol. 16(11)116007-6
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(a) (b)
(c) (d)
(e) (f)
Fig. 3 Model-derived spectra. The median spectra for each of μa(λ) (A,B), μs′(λ) (C,D), and Rt,x(λ) (E,F) were calculated for normal tissue (blue line)
and tumor (red line). Error bars represent the interquartile range. P-values from the Wilcoxon-rank sum analysis are indicated by the black line, left
column, with the green horizontal line crossing at P = 0.05. Associated AUC values are shown as the black line, right column. (Color online only.)
evaluated single spectral peaks and/or peak ratios, or combi-
nations of spectral features for tissue identification (e.g., lin-
ear discriminant analysis).15, 27–31, 33, 40 For example, Marcu and
colleagues32, 34, 35, 54 considered fluorescence peaks, peak ratios,
and fluorescence lifetime values by themselves or in a linear dis-
criminant classification algorithm. Yaroslavsky et al. estimated
the tissue optical properties in brain and relationships between
tissue types and distinctive features in their optical spectra.55
Another group used white-light reflectance to calculate the total
model-diffuse reflectance and assessed the diagnostic value of
model-derived spectral peaks.30
Quantification of PpIX concentrations in vivo has also been
used for tissue discrimination.7, 19 In this work, white-light re-
flectance spectra acquired in vivo are applied in a spectrally-
constrained light-transport model to calculate tissue optical
properties (i.e., μa, μ′s). The measured fluorescence emission
is then corrected for the distorting effects of tissue optical
attenuation, so that the absolute concentrations can be calcu-
lated. Our preliminary results with this approach showed signif-
icant diagnostic improvement compared to quantitative visual
fluorescence in the detection of a range of intracranial tumor
histologies.
Here, we assessed the diagnostic value of visible fluores-
cence, raw optical data, model-derived optical spectra, and
model-derived quantitative biomarkers. We hypothesized that
the combination of multiple optical biomarkers quantitatively
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(a) (b)
(c) (d)
(e) (f)
Fig. 4 Model-derived optical biomarkers. The median value for each of (A) cPpIX, (B) cPps, (C) cHb, (D) StO2, (E) SA, and (F) SP was calculated for
normal tissue and tumor. Error bars represent the interquartile range. A significant increase in cPpIX, cPps, cHb, and SP as well as a significant decrease
in StO2 was observed for tumor compared to normal tissue. No significant change was observed for SA.
expressed as chromophore/fluorophore concentrations and scat-
tering parameters, which individually are indicative of neoplas-
tic processes, is likely to offer the most diagnostic potential for
brain tissue discrimination during surgery. In previous work,
we found that qualitative visual assessment of ALA-induced
PpIX fluorescence4, 7, 12, 18 provides real-time intraoperative tis-
sue identification that does not interfere with surgical work-flow.
However, the requirement for high levels of PpIX accumulation
to achieve adequate signal and significant contrast for tumor
discrimination with current clinical systems is a limitation that
leads to low detection sensitivity even in high-grade gliomas
(the tumor type where this technology is considered to be most
useful).
4.2 Raw Optical Data
We assessed raw optical data (fluorescence and white-light re-
flectance) for spectrally-based tissue discrimination. We found
that straightforward spectral intensity determinations were sig-
nificantly different between normal tissue and tumor at various
wavelengths and over wavelength regions (Fig. 2). Interestingly,
the fluorescence spectra did not show significant differences
at the two emission maxima of PpIX (635 and 710 nm). We
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Table 1 Summary of ROC metrics. ROC analysis of three diagnos-
tic tests. Vis = qualitative visual imaging; the standard error is in
parenthesis.
Vis cPpIX SVM
AUC AUC AUC
Group (s.e.) (s.e.) (s.e.)
AG 0.72 0.87 0.94
(0.02) (0.03) (0.02)
LGG 0.54 0.68 0.97
(0.02) (0.07) (0.02)
HGG 0.71 0.89 0.91
(0.03) (0.03) (0.02)
RCG 0.89 0.98 0.99
(0.03) (0.02) (0.01)
observed significant changes in the full range of the reflectance
spectra with the most pronounced differences occurring in the
region of maximum hemoglobin absorption (λ = ∼450 to 580
nm). ROC analyses of the raw optical data revealed diagnostic
spectral signatures with maximum AUCs of approximately 0.75
for reflectance. Fluorescence for λ < 610 nm and in the range
λ = 650 to 680 nm revealed maximum AUC values of ap-
proximately 0.75 and 0.65, respectively. In contrast to previous
studies,36–39 we did not undertake an exhaustive search of peak
ratios to ascertain an optimal diagnostic variable, e.g., fluores-
cence peak ratios; neither did we develop a multivariate algo-
rithm using intensity peaks or peak ratios, since both strategies
are already reported in the literature. These methods are in-
dependent of the assumptions underpinning the model-derived
quantities and rely on absolute fluorophore/chromophore differ-
ences between normal tissue and tumor and their impact on the
recorded optical spectra. Fluorescence ratios of this type have
shown promise for tissue diagnostics.15 In addition, work by Lin
et al. has evaluated autofluorescence below 600 nm for tissue
classification during brain tumor resection.29, 31 However, the
parameters used for discriminaiton are not directly linked with
pathophysiological changes,56 which makes their biological in-
terpretation and significance less certain.
4.3 Model-Derived Optical Spectra
We assessed the diagnostic potential of model-derived optical
spectra for absorption, scattering, and total diffuse reflectance.
The trends were similar to those reported in the literature.31, 55, 57
The absorption spectrum in the range λ = ∼450 to 580 nm was
dominated by hemoglobin with characteristic HbO2 peaks at
∼540 and 580 nm. In the range λ = 600 to 720 nm (a subsection
of the therapeutic window investigated in this study), absorption
was significantly decreased due to low hemoglobin and water
absorption. Reduced scattering spectra showed the inverse re-
lationship between wavelength and scattering predicted by the
Rayleigh limit of Mie scattering.37, 57, 58 The shape of the diffuse
reflectance spectra showed a strong dependence on the absorp-
Table 2 Diagnostic performance summary for biomarker-based di-
agnostic algorithm. Performance summary of three diagnostic tests.
Vis = qualitative visual imaging; Classification efficiencies, sensitivities
(Sn), negative predictive values (NPV), specificities (Sp), and positive
predictive values (PPV) for tumor tissue diagnosis are tabulated.
Classification
efficiency(%) Sn (%) NPV (%) Sp (%) PPV (%)
SVM
AG 94 94 87 94 97
LGG 96 94 88 100 100
HGG 92 92 87 91 95
RCG 98 98 86 100 100
cPpIX
AG 83 84 68 78 90
LGG 63 50 44 93 95
HGG 81 75 68 91 94
RCG 97 96 75 100 100
VIS
AG 64 50 45 96 97
LGG 35 8 31 100 100
HGG 67 50 53 95 94
RCG 80 78 33 100 100
tion spectrum, whereas the magnitude appeared to be influenced
by both scattering and absorption.57
Similar to the raw data, we found significant differences be-
tween tumor and normal tissue in the model-derived spectra for
absorption, scattering, and diffuse reflectance across all wave-
lengths. Diffuse reflectance showed pronounced normal-tumor
tissue differences (P < 0.00001) in the range λ = ∼450 to
580 nm, consistent with previous work on the brain,31, 55, 57, 59
whereas the reduced scattering showed less significant differ-
ences (P < 0.05). Previous studies by Lin et al.29, 31 have re-
ported autofluorescence and diffuse reflectance spectra with
varying degrees of differences between gray matter, white mat-
ter, and tumor. In this study, normal tissue spectra were mostly
obtained from gray matter29 because the majority of control
measurements were acquired from gray matter cortex following
durotomy but prior to the first incision. While some bias may
have been introduced by the undersampling of white matter, we
measured physiologically meaningful biomarkers that represent
changes (e.g., angiogenesis, hypoxia, etc.) expected to be more
different in tumor versus normal tissue (e.g., gray or white mat-
ter) than between normal tissues (e.g., gray and white matter).
Nonetheless, further investigation of systematic differences be-
tween normal gray and white matter, and their impact on tumor
spectral and biomarker identification is warranted.
For the model-derived spectra, the absorption spectrum
yielded AUC values of approximately 0.65 in the region
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dominated by hemoglobin absorption and maximum AUC val-
ues of approximately 0.75 in the range λ = 600 to 720 nm. Lin
et al.30 also considered the diagnostic potential of model-derived
spectral peaks, specifically for diffuse reflectance, and reported
AUC values of ∼0.65 in the region 450 to 600 nm and ∼0.75 in
the region 600 to 720 nm. The small discrepancies between these
results and ones we report here can most likely be attributed to
differences in tumor histologies between the two studies and
the small number of patients involved. Future work with larger
enrollments will more closely approximate the true data distri-
bution among brain tumors and resolve these relatively minor
differences.
Model-derived optical spectra provide a theoretical frame-
work with which to understand tissue-light interactions. In
contrast to discrimination based on raw spectral data, model-
derived spectral peaks/peak ratios account for how light interacts
with tissue.37 Although this strategy incorporates a biophysical
framework that is expected to enhance the information con-
tained in the raw spectral data, it still depends on the choice of
spectral data (even following optimization) and usually requires
many variables to be extracted from the spectra for tissue clas-
sification. It also requires adequate model-data fitting for valid
predictions that are based on spectral changes that are indirectly
related to specific pathophysiological processes, and therefore,
could limit clinical interpretation and acceptance.
4.4 Quantitative Optical Biomarkers
Gliomas are a heterogeneous group of tumors ranging from well-
circumscribed WHO grade I lesions, with minimal histological
de-differentiation, to the highly invasive and malignant WHO
grade IV, glioblastoma multiforme, with high intra-tumoral
heterogeneity, necrosis, endothelial proliferation, and genetic
atypia. Conventional histopathological diagnosis of gliomas re-
quires a multifaceted assessment of tissue changes (e.g., nuclear
abnormality, endothelial proliferation, necrosis, and increased
cell density), and since they are genetically diverse with com-
plex expression profiles, combinations of biomarkers are likely
to more accurately delineate these tumors.60
Toward this end, we examined quantitative values of five
optical biomarker groups to develop a diagnostic algorithm for
intraoperative tissue classification: 1. PpIX concentration, 2.
PpIX photoproduct concentration, 3. total hemoglobin concen-
tration, 4. oxygen saturation fraction, and 5. scattering parame-
ters (SA and SP). PpIX has been shown to selectively accumulate
in brain tumors following exogenous administration of ALA.
Neoplastic changes include up- and/or down-regulated protein
expression (e.g., ferrochelatase), dysregulated substrate up-
take mechanisms, microenvironmental changes, abnormal
metabolism, increased proliferative potential, and compromised
blood-brain barrier.4, 61 We recently found a significant improve-
ment in tumor detection, including increased sensitivity in low-
grade gliomas (although at a lower level than in high-grade
tumor) when cPpIX is quantified (relative to visual assessment).7
These results demonstrate that quantitative evaluation of cPpIX
(and associated photoproducts, i.e., cPps) holds promise as an
intraoperative biomarker for guiding surgical resection (Fig. 4).
While photobleaching may occur (and be variable) in the op-
erating room, which could distort the cPpIX readings (and their
correspondence with tumor), neurosurgical resection is dynamic
(i.e., exposure times to newly presented tumor are typically
short) and we have not observed evidence of these potentiallty
deleterious effects having altered the diagnostic signature of
cPpIX in malignant versus normal tissues. Presumably, cPps orig-
inates from ALA-induced PpIX conversion (which is selectively
enhanced in tumors) and its incorporation within the diagnostic
discriminator may serve to balance loss of cPpIX signal from
photobleaching effects.
Quantitative values of StO2 and cHb are indicators of differ-
ent, but interrelated and inter-dependent biological processes.
Tissue hypoxia (i.e., low levels of StO2) is associated with malig-
nant progression and is a consequence of multiple processes oc-
curring in the tumor microenvironment (angiogenesis, balance
of aerobic/anaerobic metabolism, cell survival, and invasion).62
Specifically, hypoxia is an outcome of the metabolic adapta-
tion of tumors to anaerobic growth,5, 63 i.e., survival adapta-
tion to increased glycolysis, resulting in part from the increased
metabolism and oxygen demand of rapidly proliferating cells
and the decreased oxygen supply provided by the microvascu-
lar density.64 It may also positively alter the diffuse infiltration
of gliomas by increasing local acidic conditions.65 As a result,
lower StO2 (Fig. 4) is a biological indicator (i.e., a biomarker)
of tissue hypoxia associated with tumorigenesis.
Angiogenesis (formation of new blood vessels) occurs in tu-
mors at increased levels in a disorganized and inefficient fashion
(tortuous dead-ends, overproduction of capillary networks, etc.)
and with abnormal vascular structure and performance (highly
permeable and dilated vessels).5, 63, 66 It is a pre-requisite for tu-
mor formation, growth, and progression.63 Angiogenesis is also
related to hypoxia because new vessels form in tumors partly as
a physiological response to lack of oxygen.62, 64, 65, 67 Regions of
increased vasculature have increased levels of blood elevating
cHb and making it an indicator of tumor angiogenesis (Fig. 4).
Tumors undergo morphological changes at the tissue, cellu-
lar, and sub-cellular levels. Changes in nuclear size and shape,
organelle content, and morphology occur at the cellular and
sub-cellular scales, whereas increased cellular density,, and dis-
organized tissue networks and vasculature occur at the tissue
level. Elastic scattering of light in tissue reflects the size and
shape of scatterers, which can be related to these underlying
sub-cellular, cellular, and tissue characteristics.37, 58, 68, 69 Here,
we used a wavelength-dependent power law μ′s = SAλ−SP to
model the reduced scattering spectrum, μs′(λ), yielding quan-
titative scattering parameters, SA and SP, corresponding to the
scattering amplitude and power of tissue. Scattering parame-
ters serve as biomarkers of morphological changes that occur in
tumors, typically being increased by the inhomogeneities that
exist58 (Fig. 4).
These quantitative biomarkers serve as indicators of impor-
tant biological processes (e.g., angiogenesis, hypoxia) occurring
in gliomas. Given the inter- and intra-tumor heterogeneity of
gliomas and the multifaceted character of the neoplastic pro-
cesses involved, intraoperative tumor (Table 1) identification is
likely to benefit from the evaluation of multiple factors (i.e.,
biomarkers).
4.5 Diagnostic Algorithm
We developed an SVM algorithm, commonly applied in gen-
eral, nonlinear problems,42–44 to incorporate the individual
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predictive and diagnostic contributions from the five model-
derived quantitative biomarkers (i.e., cPpIX, cPps, cHb, StO2, and
SP) for tissue classification. We found superior diagnostic per-
formance resulted from this multiple biomarker-based strategy
[classification efficiency = 94%; ROC AUC = 0.94(0.02)] rel-
ative to raw spectroscopic fluorescence, model-derived spectra,
and intraoperative visual fluorescence [classification efficiency
= 64%; ROC AUC = 0.72(0.02)].
ALA-induced PpIX fluorescence as visualized with a state-
of-the-art surgical microscope showed a diagnostic perfor-
mance in LGG that is marginally greater than chance [AUC
of 0.54(0.02)]. As expected, visible fluorescence in HGG per-
forms significantly better with an AUC of 0.71(0.03). With cPpIX
as a single biomarker, the AUC for HGG increases to 0.89(0.03)
and also improves to 0.68(0.07) for LGG. Interestingly, the di-
agnostic performance in LGG with cPpIX is comparable to qual-
itative visual fluorescence in HGG, but does not achieve the
performance attained with cPpIX. Multiple quantitative biomark-
ers offer significantly improved diagnostic performance (P
< 0.00001), especially in LGG [to 0.97(0.02) from 0.54(0.02)
using visible fluorescence and 0.68(0.07) using cPpIX alone].
These encouraging results suggest that multiple quantitative
biomarkers may be able to detect both tumor bulk and infiltrat-
ing margins, especially in low-grade gliomas where the impact
on patient prognosis and survival could be substantial.
While these data are promising, the results were generated
from a nonrandomized study with a limited number of patients.
Nonetheless, as a proof-of-concept, the strategy does signifi-
cantly improve tumor detection, although further validation of
its predictive power in a larger cohort of gliomas is still required.
However, the balance between sensitivity and specificity may be
surgeon and even case-specific, since concerns for patient safety
and/or the risk of functional impairment secondary to surgery
often independently override the resection decision of whether
tumor remains in the operative field. From this perspective, the
comparative analysis of diagnostic performance presented here
is somewhat simplistic, and a robust diagnostic algorithm that
the surgeon could adjust for (or even during) a case to empha-
size sensitivity or specificity might be more attractive, since the
probability of tumor is only one factor weighed in the decision
to resect any given portion of brain tissue. In practice, intraop-
erative probe-based sampling of brain tissue is likely to be of
modest value to the surgeon because of its limited capacity to
efficiently interrogate the surgical field. Hence, discrimination
algorithms of the type described here will not have much impact
in the operating room (OR) unless wide-field imaging technol-
ogy is developed, which can recover the quantitative optical
biomarkers that have been used.
5 Conclusions
Based on retrospective data collected in 10 glioma patients,
intraoperative identification of tumor is significantly improved
when multiple optical biomarkers are quantified and incorpo-
rated into a diagnostic algorithm based on support vector ma-
chine classification relative to qualitative visual fluorescence
or characteristics obtained from raw optical spectra or model-
derived spectral features. Prospective validation of the predictive
power of the algorithm in a larger cohort of patients remains to be
completed and even the diagnostic training of the approach may
benefit from additional data collected from a broader number of
tumors meeting the low and high grade WHO histopathological
criteria. While the quantification of chromophore/fluorophore
concentrations and scattering parameters opens the door to the
inclusion of multiple biomarkers representing processes char-
acteristic of tumor biology in an algorithm that extends diag-
nostic performance beyond traditional single biomarker (e.g.,
PpIX), single modality (e.g., fluorescence) or “black box” spec-
tral techniques, clinical utility of the method will necessitate the
development of an equivalent wide-field approach.
Acknowledgments
This work was supported in part by National Institutes of Health
Grant No. R01NS052274-01A2 (D. W. Roberts) and award K25
CA138578 (F. Leblond). Carl Zeiss (Carl Zeiss Surgical GmbH,
Oberkochen, Germany) and Medtronic Navigation (Medtronic,
Louisville, Colorado) provided the fluorescence-enabled
OPMI Pentero R© operating microscope and StealthStation R©
Treon R© navigation system, respectively. DUSA Pharmaceuti-
cals (DUSA Pharmaceuticals, Tarrytown, New York) supplied
the ALA. Drs. Kim and Wilson have a provisional patent
(61,297,969) for the intraoperative probe used in this study.
Appendix A
An SVM classification algorithm finds the optimal (unique) sep-
arating hyperplane (OSH) between two classes by maximizing
the margin, δ, in feature space between the closest point(s) of
both classes. Individual data points (e.g., an interrogated tissue
site) are known as objects and are composed of a set of predic-
tor variables or attributes (i.e., the parameters used to describe
the individual data points, such as cPpIX, cHb in this work). An
object, x, has n attributes (i.e., coordinates) in input space, RI,
such that xi = (x1, x2, . . . xn), where xj is a real number, xj ∈ R
for j = 1, 2, . . . , n. Each object belongs to a given class yi ∈ {–1,
1}. SVM then maps objects from the original input space on
to a higher dimensional feature space using nonlinear functions
known as feature functions.42, 44, 45, 70
We consider a training set, T, of m objects and their classes, T
= {(x1, y1), (x2, y2), . . . , (xm, ym), }. A set of features functions,
φ1, φ2, . . . , φh, is defined that map any object x into vector φ(x):
x = (x1, x2, . . . , xn) →
φ(x) = (φ1(x), φ2(x), . . . , φh(x)) .
(9)
After mapping, we form a set of objects in feature space, RF,
based on their individual class assignments:
(T ) = [φ(x1, y1), φ(x2, y2), . . . , φ(xm, ym)] . (10)
The training set in feature space (i.e., φ(T)) can be linearly clas-
sified if the appropriate feature functions (i.e., φ(x)) are used.
Transformed attributes are known as features, and a vector is the
set of features that make up an object. vectors that constrain the
margin width are known as support vectors.42, 44, 45, 70 in feature
space, objects can be separated by class with associated error
costs when no perfect classification is achievable, which be-
comes a constrained-optimization problem (i.e., to find the OSH
minimization of a quadratic function under linear constraints)
that can be solved by a Lagrangian transformation, which
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generalizes the problem to both linear and nonlinear SVM mod-
els. Here, we used a sequential minimal optimization algorithm
to solve the optimization problem. In a nonlinear SVM, the
objects’ class (i.e., xk) is given by
class(xk) = sign [w · φ(xk) + b]
= sign
[
m∑
i=1
λi yiφ(xi ) · φ(xk)
]
, (11)
where  = (λ1, λ2, . . . , λm) is the set of Lagrange multipliers
from the training objects x = (x1, x2, . . . , x m). Under certain
conditions (Mercer’s conditions), an inner product in feature
space has an equivalent kernel in input space. In this case, simple
nonlinear kernel functions can be used to compute φ(xi) ·φ(xk)
and perform the nonlinear mapping of feature functions, such
that
K (Xi , X j ) = φ(Xi ) · φ(X j ). (12)
The training objects with λi > 0 represent the support vectors.
The objects with λi = 0 are not important in the SVM model,
and all that is needed to classify objects are the support vectors
and λi > 0.42, 45, 70
We optimized SVM parameters (e.g., kernels functions) and
applied the commonly used Gaussian radial basis function for
classification,
K (Xi , X j ) = φ(Xi ) · φ(X j ) = e−
‖x−y‖2
2σ2 , (13)
where σ controls the shape of the separating hyperplane. Ker-
nel function parameter optimization for σ and the soft margin
constraint occurred by performing a grid search from 0.05 to 10
for σ and from 1 to 200 for the soft margin constraint to find the
highest classification efficiency.45 We optimized the SVM clas-
sification algorithm parameters with a value of σ = 0.2, a soft
margin penalty error of 81 (to provide a balance between com-
plexity, over-fitting, and tolerance of the diagnostic algorithm
for misclassification) and an average of 179 support vectors.45
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